Suven Life Sciences Ltd. has reported new muscarinic acetylcholine M4 receptor positive allosteric modulators (PAMs) potentially useful for the treatment of schizophrenia, Alzheimer’s disease, Parkinson’s disease, depression, bipolar disorders, Huntington’s disease, attention deficit hyperactivity disorder and pain, among others.